These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22773665)

  • 41. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Shen H
    Mol Carcinog; 2017 Oct; 56(10):2279-2289. PubMed ID: 28543546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
    Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
    Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
    Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxytetracycline have the therapeutic efficiency in CD133
    Song Y; Kim IK; Choi I; Kim SH; Seo HR
    Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.
    Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H
    J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Reversal of stemness in multidrug-resistant hepatocellular carcinoma cells by SIS3].
    Yan W; Wen T; Lin S; Liu Z; Yang W; Wu G
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):731-5. PubMed ID: 26813590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
    Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
    Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
    Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
    J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
    Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
    Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma.
    Zenali MJ; Tan D; Li W; Dhingra S; Brown RE
    Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
    Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
    Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of CD133-positive stem cells in repeated recurrence of hepatocellular carcinoma after liver transplantation: a case report.
    Toshima T; Yoshizumi T; Uchiyama H; Ikegami T; Soejima Y; Ikeda T; Kawanaka H; Yamashita Y; Morita M; Oki E; Mimori K; Sugimachi K; Saeki H; Watanabe M; Shirabe K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):383-8. PubMed ID: 24511670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation.
    Deng G; Zeng S; Qu Y; Luo Q; Guo C; Yin L; Han Y; Li Y; Cai C; Fu Y; Shen H
    J Exp Clin Cancer Res; 2018 Jul; 37(1):156. PubMed ID: 30012194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of liver cancer stem cells in donor liver allocation for patients with hepatocellular carcinoma.
    Zhou J; Hu Z; Li Z; Yu P; Wu J; Zheng S
    Postgrad Med; 2013 Nov; 125(6):24-30. PubMed ID: 24200758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
    Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
    J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells.
    Chang PH; Sekine K; Chao HM; Hsu SH; Chern E
    Sci Rep; 2017 Apr; 8():45751. PubMed ID: 28367998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    Mano Y; Yoshio S; Shoji H; Tomonari S; Aoki Y; Aoyanagi N; Okamoto T; Matsuura Y; Osawa Y; Kimura K; Yugawa K; Wang H; Oda Y; Yoshizumi T; Maehara Y; Kanto T
    J Gastroenterol; 2019 Nov; 54(11):1007-1018. PubMed ID: 30941514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta.
    You H; Ding W; Rountree CB
    Hepatology; 2010 May; 51(5):1635-44. PubMed ID: 20196115
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
    Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.